Clinical trials: Resectable Small Cell Lung Cancer
Non-Small Cell Lung Cancer
A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
To evaluate the safety and efficacy of SYS6010 combined with osimertinib as neoadjuvant therapy for patients with resectable EGFR mutation non-squamous non-small cell lung cancer.
- Trial name
- NCT07256509
- Testing
- SYS6010, Osimertinib, Pemetrexed
- Volunteers
- 120 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Non-small Cell Lung Cancer (NSCLC)
Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments
The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small…
- Trial name
- NCT06448793
- Testing
- Approved Non-small Cell Lung Cancer (NSCLC) therapies
- Where
- United Kingdom
- Volunteers
- 650 people
- Sponsor
- Bristol-Myers Squibb
Resectable Non-Small-Cell Lung Cancer
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC
This study aims to explore the efficacy and safety of thymosin α-1 (Tα1) plus chemotherapy and PD-1 inhibitors as neoadjuvant therapy for operable non-small cell lung cancer
- Trial name
- NCT06607926
- Testing
- Thymosin Alpha 1, Tislelizumab, Platinum-doublet chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xuanwu Hospital, Beijing
NSCLC, EGF-R Positive Non-Small Cell Lung Cancer
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
Icotinib is a first-generation inhibitor of EGFR-tyrosine kinase inhibitor in patients with non-small-cell lung cancer (NSCLC). Here we will evaluate neoadjuvant Icotinib with chemotherapy prior to surgery, in patients with…
- Trial name
- NCT05132985
- Testing
- Icotinib, Cisplatin, Carboplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Non-Small Cell Lung Cancer
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned.
- Trial name
- NCT06465329
- Testing
- Cemiplimab, Platinum-based chemotherapy, REGN7075
- Where
- 47 sites in United States, Brazil and 4 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Non-Small Cell Lung Cancer
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
This is a phase 1/2 study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable non-small cell lung cancer (NSCLC).
- Trial name
- NCT06088771
- Testing
- Dupilumab, Cemiplimab
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Stage IIIA Non-small Cell Lung Cancer
Fludeoxyglucose F 18 PET/CT Scans in Predicting Therapy Response in Patients With Stage IIIA Non-Small Cell Lung Cancer Undergoing Chemoradiation
This clinical trial studies fludeoxyglucose F 18 (FDG) positron emission tomography (PET)/computed tomography (CT) in predicting chemoradiation therapy (CRT) failure in patients with stage IIIA non-small cell lung cancer (NSCLC).
- Trial name
- NCT01314677
- Testing
- positron emission tomography/computed tomography (PET/CT), fludeoxyglucose F 18
- Sponsor
- City of Hope Medical Center
Non-Small Cell Lung Cancer, Adebrelimab
A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer
To evaluate the major pathological response rate of Adibelimab combined with Apatinib neoadjuvant therapy in resectable non-small cell lung cancer.
- Conditions
- Non-Small Cell Lung Cancer, Adebrelimab, Apatinib
- Trial name
- NCT07031154
- Testing
- Adebrelimab, Apatinib
- Where
- China
- Volunteers
- 43 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Stage III Non-small Cell Lung Cancer
Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC
Introduction: Although PACIFIC regimen definitive concurrent chemoradiotherapy (CRT) followed by Durvalumab consolidation therapy is considered the standard of care for most of stage III NSCLC patients, neoadjuvant immunotherapy…
- Trial name
- NCT05157542
- Testing
- Durvalumab, nanoparticle albumin bound paclitaxel, low dose radiation therapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Juan LI, MD
Small Cell Lung Cancer (SCLC)
Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial
This study is a randomized, open-label, multicenter exploratory research aiming to evaluate the efficacy and safety of Adebrelimab in combination with chemotherapy (etoposide and platinum-based therapy) as neoadjuvant treatment…
- Trial name
- NCT06485544
- Testing
- Adebrelimab + Etoposide + Platinum-based Therapy, Etoposide + Platinum-based Therapy
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Tang-Du Hospital
EGFR, Non-Small Cell Lung Cancer
Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
This study targeted patients with resectable stage II-IIIA non-small cell lung cancer with EGFR mutation
- Conditions
- EGFR, Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer, Pemetrexed
- Trial name
- NCT06755684
- Testing
- Befotertinib combined Bevacizumab, Befotertinib combined platinum-based double chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peng Zhang
Non-small Cell Lung Cancer
Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIA-IIIB Resectable NSCLC (FORESEE)
In this single-arm, phase II clinical trial, patients with resectable, EGFR-mutated, stage II-IIIB NSCLC received neoadjuvant therapy with furmonertinib (oral, 80 mg once daily, stopped 1 week preoperatively) in combination with…
- Trial name
- NCT05430802
- Testing
- Furmonertinib+cisplating/pemetrexed
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tang-Du Hospital
Non-small Cell Lung Cancer
Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy
This is a prospective, single arm, single center clinical study to determine the efficacy and safety of pablizumab combined with apatinib and neoadjuvant chemotherapy in patients with stage iia-iiia non-small cell lung cancer.
- Trial name
- NCT04968002
- Testing
- pablizumab combined with apatinib and neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
NSCLC (Non-small Cell Lung Cancer)
Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC
This is a Phase II single-arm study designed to evaluate the efficacy and safety of cryoablation combined with tislelizumab and platinum-based doublet chemotherapy as neoadjuvant therapy, followed by adjuvant tislelizumab therapy…
- Trial name
- NCT06939127
- Testing
- Neoadjuvant Cryoablation Combined with Tislelizumab and Chemotherapy, Surgery, Adjuvant tislelizumab
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-small Cell Lung Cancer
Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer
In the randomized, multicenter Phase II clinical trial, we aim to evaluate the efficacy and safety of Lazertinib monotherapy or the combination of Lazertinib and cytotoxic chemotherapy as neoadjuvant therapy in patients with…
- Trial name
- NeoLazer (NCT06268210)
- Testing
- Lazertinib+Pemetrexed+Carboplatin, Lazertinib
- Where
- South Korea
- Volunteers
- 160 people
- Sponsor
- Yonsei University
NSCLC Stage II
Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients
This study aims to evaluate the efficacy and safety of JSKN016 combined with toripalimab and carboplatin as a neoadjuvant treatment regimen in patients with resectable stage II-III NSCLC.
- Trial name
- NCT07493980
- Testing
- JSKN016 + Toripalimab + Carboplatin
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
NSCLC, NSCLC (Non-small Cell Lung Cancer)
Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial
The primary objective of this study is to evaluate whether neoadjuvant SBRT as an immunomodulator in combination with apalolimab and toripalimab (QL1706) plus chemotherapy improves the pathological complete response (pCR) rate in…
- Trial name
- NCT07286942
- Testing
- apalolimab and toripalimab (QL1706)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Non-Small Cell Lung Cancer
Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC
EGFR-TKI has firmly established itself as a first-line treatment for advanced lung cancer with EGFR-sensitive mutations, and the ADAURA study has added to its indications for use as postoperative adjuvant therapy in early- and…
- Trial name
- NCT05987826
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
NSCLC (Non-small Cell Lung Cancer), EGFR Activating Mutation
High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC
This is a Phase II, single-arm, open-label, multicenter clinical study aimed at evaluating the efficacy and safety of Firmonertinib 160 mg combined with Bevacizumab as neoadjuvant therapy in patients with resectable stage II-IIIB…
- Conditions
- NSCLC (Non-small Cell Lung Cancer), EGFR Activating Mutation, Resectable Lung Non-Small Cell Carcinoma
- Trial name
- HOFIBREN (NCT07182708)
- Testing
- Firmonertinib Mesilate Tablets, Bevacizumab injection
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Peking University Cancer Hospital & Institute